Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3049% below fair value
$1.09−0.15 (-11.74%)
Close on Nov 18, 2026Market cap $5.01MP/E –Yield –
Biomerica revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Biomerica's revenue for the twelve months ending Aug 31, 2026 was $4.34M, down 11.2% year over year. For fiscal 2026 it was $4.45M, down 16.2% from the year before. Over ten years it grew -1.4% a year on average. The highest annual figure on record is $18.87M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $4.45M | -16.2% |
| FY2025 | May 31, 2025 | $5.31M | -1.9% |
| FY2024 | May 31, 2024 | $5.42M | +1.4% |
| FY2023 | May 31, 2023 | $5.34M | -71.7% |
| FY2022 | May 31, 2022 | $18.87M | +162.1% |
| FY2021 | May 31, 2021 | $7.20M | +7.6% |
| FY2020 | May 31, 2020 | $6.69M | +28.7% |
| FY2019 | May 31, 2019 | $5.20M | -6.5% |
| FY2018 | May 31, 2018 | $5.56M | -3.9% |
| FY2017 | May 31, 2017 | $5.79M | +12.7% |
| FY2016 | May 31, 2016 | $5.14M | +3.6% |
| FY2015 | May 31, 2015 | $4.96M | -3.1% |
| FY2014 | May 31, 2014 | $5.12M | -20.9% |
| FY2013 | May 31, 2013 | $6.47M | +6.4% |
| FY2012 | May 31, 2012 | $6.08M | +24.1% |
| FY2011 | May 31, 2011 | $4.90M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $1.27M | -8.3% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $875.00K | +16.8% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $987.00K | -11.8% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $1.21M | -26.0% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $1.38M | -23.6% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $749.00K | -32.9% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $1.12M | +10.0% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $1.64M | +4.4% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $1.81M | +5.5% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $1.12M | +0.7% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $1.02M | -8.5% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $1.57M | +5.7% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $1.71M | +4.6% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $1.11M | -79.1% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $1.11M | -85.5% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $1.48M | -68.1% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $1.64M | +29.7% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $5.30M | +403.0% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $7.66M | +111.1% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $4.65M | +238.6% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $1.26M | +10.3% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $1.05M | -61.3% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $3.63M | +208.3% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $1.37M | -14.0% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $1.14M | -4.2% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $2.72M | +133.7% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $1.18M | -6.7% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $1.60M | +6.4% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $1.19M | -6.2% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $1.17M | +3.1% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $1.26M | -8.3% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $1.50M | -7.0% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $1.27M | -11.9% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $1.13M | -22.0% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $1.38M | -8.3% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $1.61M | +12.7% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $1.44M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $1.45M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $1.50M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $1.43M | – |
See a number that looks wrong?